Plain-English translation of NCT03970720 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
Many people with type 1 diabetes lose the ability to feel warning signs when their blood sugar drops too low—a condition called hypoglycemia unawareness. This study tests whether , a medication already approved by the FDA for other uses, can restore those warning feelings and help people recognize and treat dangerous low blood sugar episodes.
Hypoglycemia unawareness is a serious problem for people with type 1 diabetes because it increases the risk of severe, life-threatening low blood sugar episodes by 25 times or more. Currently, no proven treatments exist to restore this awareness, so researchers are testing whether this medication could fill that gap.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will take either the study medication or a placebo (inactive pill) four times daily for four weeks. You will also undergo a supervised low blood sugar test (called a hypoglycemic clamp) to measure how well you can sense dangerously low blood sugar before and after treatment. Throughout the study, you'll be carefully monitored by the research team to ensure your safety.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States